GlassScriptPhysician profile
Sara Wingate
NPI 1801291554
$7,786.79
in general payments reported to CMS, 2019-2025
46 companies · $1,305 in 2025
The $1,305 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $716 · 2022: $833 · 2023: $1,872 · 2024: $3,060 · 2025: $1,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,973 · Education: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,973.43 |
| Education | $264.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $908.93 | 2021-2025 | |
| Incyte Corporation | $646.89 | 2023-2025 | Opzelura |
| Lilly USA, LLC | $632.98 | 2021-2025 | Taltz, Olumiant, Mounjaro |
| Novo Nordisk INC | $589.02 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Biotech, INC. | $514.57 | 2023-2025 | Tremfya, Simponi Aria, Simponi |
| Arcutis Biotherapeutics, INC. | $418.32 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $403.36 | 2023-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $379.13 | 2023-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $348.28 | 2024-2025 | |
| Genzyme Corporation | $345.19 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $342.66 | 2023-2025 | Winlevi, Absorica Ld |
| Mayne Pharma Commercial LLC | $280.42 | 2023-2025 | |
| Dermavant Sciences, INC. | $213.38 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.77 | 2021-2024 | Jardiance, Spevigo |
| Ucb, INC. | $171.45 | 2024-2025 | Bimzelx |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Wingate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.